Global MarketsDURECT outlines $20M Section 3 trial for larsucosterol in alcohol-associated hepatitis By StockWaves Last updated: March 27, 2025 0 Min Read SHARE DURECT outlines $20M Section 3 trial for larsucosterol in alcohol-associated hepatitis Sign Up For Daily NewsletterBe keep up! Get the latest breaking news delivered straight to your inbox. Leave this field empty if you're human: By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time. Share This Article Facebook Twitter Copy Link Print Previous Article Breakout shares to purchase or promote: Sumeet Bagadia recommends 5 shares to purchase at present — 27 March 2025 Next Article Gynecological Cancers in India Anticipated to Rise by 55% by 2040; Specialists Name for Pressing Motion and Preventive Measures Leave a commentLeave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment *Name * Email * Website Save my name, email, and website in this browser for the next time I comment. FacebookLikeTwitterFollowPinterestPinInstagramFollowSubscribe NowSubscribe to our newsletter to get our newest articles instantly! Leave this field empty if you're human: Most Popular Arisinfra Options Rs 500 crore IPO hits D-Avenue June 18, 2025 RailTel Corp Shares Surge 3% on Rs 43 Crore LoI June 18, 2025 Are Tesco shares the one free lunch on the FTSE 100? June 18, 2025 Trump Calls for Iran’s ‘Unconditional Give up’ — Inventory Futures Stay Regular, Protection Shares Commerce Larger In After-Hours Buying and selling – Elbit Techniques (NASDAQ:ESLT), iShares U.S. Aerospace & Protection ETF (BATS:ITA) June 18, 2025 Suspended for not engaged on weekend, man goes on trip; netizens name it a ‘win’ June 18, 2025
